1. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals;Vitaku;J. Med. Chem.,2014
2. An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals;Baumann;Beilstein J. Org. Chem.,2011
3. Walji, A., Berger, R., Stump, C.A., Schlegel, K.A.S., Mulhearn, J.J., Greshock, T.J., Wang, D., Fraley, M.E., and Jones, K.G. (2017). 3-Aryl and Heteroaryl Substituted 5-Trifluoromethyl Oxadiazoles as Histone Deacetylase 6 (HDAC6) Inhibitors. (WO Pat. 2017222951A1).
4. Walji, A., Berger, R., Stump, C.A., Schlegel, K.A.S., Mulhearn, J.J., Greshock, T.J., Ginnetti, A.T., Wang, D., Stachel, S.J., and Fraley, M.E. (2017). 3-Heterocyclyl Substituted 5-Trifluoromethyl Oxadiazoles as Histone Deacetylase 6 (HDAC6) Inhibitors. (WO Pat. 2017222950A1).
5. Mandegar, M.A., Patel, S., Ding, P., Bhatt, U., Holan, M., Lee, J., Li, Y., Medina, J., Nerurkar, A., and Seidl, F. (2021). Fluoroalkyl-Oxadiazoles and Uses Thereof. (WO Pat. 2021127643A1).